For people living with type 2 diabetes, the day is a long series of small decisions — what to eat, when to walk, whether that snack matters. A growing body of evidence now puts a striking number on how much technology can help: patients using continuous glucose monitors (CGMs) spend roughly five more hours each day with their blood sugar in the healthy target range compared with finger-prick testing alone. It is the kind of finding our health coverage follows closely, because time-in-range has become one of the most meaningful measures of diabetes control.
How continuous monitors change behaviour
A CGM is a small sensor worn on the arm or abdomen that measures glucose every few minutes and streams the readings to a phone app, complete with trend arrows. Instead of a handful of snapshots a day, patients see the full film: the spike after white rice, the gentle dip after a ten-minute walk, the effect of a poor night’s sleep. That feedback loop is the real therapy. People learn their personal responses to food and activity within days, and clinicians can adjust medication based on patterns rather than guesswork. The American Diabetes Association has steadily expanded its CGM recommendations as this evidence has accumulated.
Why five hours in range matters
Time-in-range — typically the share of the day spent between 70 and 180 mg/dL — correlates strongly with long-term outcomes. Sustained high glucose damages blood vessels, nerves, eyes and kidneys; five extra hours a day in range compounds into years of reduced exposure. Studies also link CGM use to fewer dangerous hypoglycaemic episodes, because alarms warn patients before they crash. For health systems, the economics are increasingly hard to argue with: preventing complications is far cheaper than treating them, which is why insurers and public programmes keep widening eligibility beyond insulin users.
Barriers that still need solving
Access remains uneven. Sensors are consumables replaced every 10 to 14 days, costs add up, and not every primary-care clinician feels confident interpreting CGM data. There is also a learning curve: some patients feel overwhelmed by constant data, and alarm fatigue is real. The National Institute of Diabetes and Digestive and Kidney Diseases continues to fund research into who benefits most and how to support them. Cheaper over-the-counter sensors, now reaching the market, may do more to close the gap than any single study.
What patients actually do with the data
Ask long-term CGM users what changed and few mention the hardware; they talk about discoveries. A morning bowl of cereal that looked harmless turns out to spike glucose for three hours. A short walk after dinner flattens the curve more than any supplement ever did. Sleep, stress and even the order in which food is eaten leave visible fingerprints on the graph. Clinicians call this biofeedback-driven learning, and it explains why benefits persist: the device teaches, then the habits remain even on days the sensor is off. Support programmes increasingly pair new users with a few coaching sessions to interpret patterns, set realistic targets and avoid the anxiety that a wall of numbers can cause. The technology’s real triumph is not measurement — it is turning an invisible condition into something a person can see, understand and steadily steer.
The bottom line
Five extra hours a day in a healthy range is not a marginal gain — it is a transformation in daily disease burden, achieved not with a new drug but with timely information. As prices fall and guidelines broaden, the question for type 2 diabetes care is shifting from whether CGMs help to how quickly everyone who could benefit can get one.